Aglaris to Present and Attend Upcoming UK Conferences
Key conferences include BIA, Phacilitate SIG and Anglo Nordic
Stevenage, UK and Madrid, Spain, 25 May 2017 – Aglaris Ltd (Aglaris), an innovative cell culture platform technology company, announces it will be attending and presenting a company overview at the following conferences. Aglaris is focussed on the provision of automated transformative cell culture technologies that address issues in personalised, regenerative and cellular therapies.
25 May 2017, The Oxford Belfry, Milton Common, Milton Common, OX9 2JW
Aglaris to present at the Innovation showcase at the event on 25 May at 14:00.
The flagship UK CEO and Investor Forum is hosted at the Oxford Belfry, at Milton Common, Oxford. This invite only forum is attracts C-suite and senior managers in corporate organisations and investors, and known for its peer-to-peer networking, discussions and debates.
30 & 31 May 2017, Hopetoun House, Queensferry, Edinburgh EH30 9SL
Aglaris to present and host meetings.
Phacilitate’s inaugural SIG, is a unique and exclusive think tank drawing together the cell and gene therapy sector’s manufacturing decision makers with the ‘do-ers’: namely the bioprocess developers and engineers tasked with sourcing, selecting and implementing automated solutions.
31 May 2017, 8 Northumberland Ave, London WC2N 5BY
Aglaris to present and host meetings. The company presentation is at 14:00 in the Technologies Room.
This year’s fourteenth Anglo Nordic conference takes place at the prestigious 8 Northumberland Avenue, just a few steps from Trafalgar Square in central London. The conference provides a platform to meet decision makers at leading and upcoming drug discovery and medtech companies from the Anglo-Nordic regions, international pharmaceuticals and investment firms. Belgium is this year’s guest country.
Dr David Horna
Dr Miquel Costa
NOTES TO EDITOR
About Aglaris Ltd
Aglaris Limited (Aglaris) is developing innovative, automated cell culture platform technologies. Set up in 2014, Aglaris aims to solve the bottleneck in cell and tissue manufacturing, currently inhibiting the wider application of cell-based therapies within regenerative medicine.
Aglaris has a clear aspiration to provide an enabling technology platform to make cell therapy a reality. Novel platforms and stem cell approaches are emerging as potentially promising therapies across a wide range of disease areas. This fast-growing global stem cell market is expected to increase threefold and reach £135 billion by 2020. To meet the needs of cell therapies, cell production needs to be more affordable and technically competitive. Aglaris has developed the Facer 1.0 prototype (integrating the Aglaris technology in an automated bioreactor) and a number of ancillary technologies (e.g., microparticles, filtration system, sensor array etc.) which are currently under validation at Aglaris’ headquarters at the Stevenage Bioscience Catalyst (UK) and its laboratory premises at Parque Tecnológico de Madrid (Spain).
The experienced management team and board bring a proven track record of clinical and scientific credentials in founding, developing and commercialisation of technologies. Investments in Aglaris to date include grants and venture funding from renowned public and private institutions. For further information, please visit www.aglaris.co.uk.